Lantheus Medical Imaging, a worldwide manufacturer and distributor of diagnostic imaging agents, announced today that it has entered into a 10-year agreement with FUJIFILM RI Pharma Co., Ltd. to supply imaging agent kits for SPECT imaging in Japan. This agreement comes on the heels of an earlier 10-year agreement with FUJIFILM RI Pharma, and went into effect Jan. 1, 2013.

"We are pleased to continue our long-term collaborative relationship with FRI [FUJIFILM RI Pharma], which we've successfully developed over the past ten years," said Don Kiepert, president and chief executive officer at Lantheus, in a statement. "Japan represents one of the largest markets for imaging agents worldwide."

Cardiolite and Neurolite -- which Lantheus will continue to supply to FUJIFILM RI Pharma in finished form as well as raw form for the manufacture and distribution in unit dose form -- are technetium-based radiopharmaceutical imaging agents. Cardiolite is used in SPECT imaging to diagnose coronary artery disease and Neurolite is used in SPECT brain imaging for localization of stroke in patients who have already been diagnosed.

More Industry Headlines